Close

Lenti-BCMA CAR (scFv-28ζ, C12A3.2)-VP (VP-CAR-LC533)

The ready-to-use lentiviral particles of Lenti-BCMA CAR (scFv-28ζ, C12A3.2)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (C12A3.2)-CD28-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Specifications

  • Type of Therapeutics
  • Chimeric Antigen Receptor
  • Target
  • BCMA
  • Expression Cassette
  • scFv (C12A3.2)-CD28-CD3ζ
  • Clone
  • C12A3.2
  • Promotor
  • EF1a
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • Multiple myeloma

Target

  • Introduction
  • The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.
  • Alternative Names
  • BCM; BCMA; CD269; TNFRSF13A,TNFRSF17

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.